{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:44:33Z","timestamp":1781210673397,"version":"3.54.1"},"reference-count":46,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010609","type":"journal-article","created":{"date-parts":[[2013,6,24]],"date-time":"2013-06-24T17:59:50Z","timestamp":1372096790000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults"],"prefix":"10.1002","volume":"2016","author":[{"given":"Mattias","family":"Linde","sequence":"first","affiliation":[{"name":"Norwegian University of Science and Technology; Department of Neuroscience; Trondheim Norway"},{"name":"St. Olav\u2019s University Hospital; Norwegian Advisory Unit on Headaches; Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim M","family":"Mulleners","sequence":"additional","affiliation":[{"name":"Canisius Wilhelmina Ziekenhuis; Department of Neurology; PO Box 9015 Nijmegen Netherlands 6500 GS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P","family":"Chronicle","sequence":"additional","affiliation":[{"name":"University of Hawaii at Manoa; (Deceased) Department of Psychology; Manoa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas C","family":"McCrory","sequence":"additional","affiliation":[{"name":"Duke University Medical Center; Department of Medicine; Durham NC USA 27710"},{"name":"Durham Veterans Affairs Medical Center; Center for Health Services Research in Primary Care; 508 Fulton St Durham NC USA 27705"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,6,24]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD010609-BIB0001|cit1","first-page":"145","article-title":"Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study","volume":"151","author":"Trapani","year":"2000","journal-title":"Clinica Terapeutica"},{"issue":"7","key":"10.1002\/14651858.CD010609-BIB0002|cit2","first-page":"603","article-title":"Effectiveness and safety of gabapentin in the preventive treatment of migraine","volume":"35","author":"Jimenez-Hernandez","year":"2002","journal-title":"Revista de Neurologia"},{"key":"10.1002\/14651858.CD010609-BIB0003|cit3","unstructured":"Feuerstein T Quebe-Fehling E A double-blind, placebo-controlled, parallel-group, multicenter study of the safety and efficacy of gabapentin (CI-945) as a prophylactic interval therapy in patients with common migraine (Protocols 879-201, -205, -206, -207, -209) Research Report No. RR 4301-00066. Freiburg: Goedecke AG Research and Development; June 25, 1990. Available at: http:\/\/dida.library.ucsf.edu\/pdf\/crr13j10"},{"key":"10.1002\/14651858.CD010609-BIB0004|cit4","unstructured":"Magnus-Miller L Bernstein P Caswell K Double-blind, randomized, placebo-controlled, multicenter trial to determine the efficacy and safety of Neurontin\u00ae (gabapentin) in migraine prophylaxis administered in doses divided three times a day (TID) (Protocol 945-220) Research Report No. RR 995-00074. Morris Plains, NJ: Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company Medical and Scientific Affairs Department; August 24, 1999. Available at: http:\/\/dida.library.ucsf.edu\/pdf\/arr13j10"},{"key":"10.1002\/14651858.CD010609-BIB0005|cit5","unstructured":"Magnus-Miller L Bernstein P Caswell K Double-blind, randomized, placebo-controlled, multicenter trial to determine the efficacy and safety of Neurontin\u00ae (gabapentin) in migraine prophylaxis (Protocol 945-217) Research Report No. RR 995-00085. Morris Plains, NJ: Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company Medical and Scientific Affairs Department; January 20, 2000. Available at: http:\/\/dida.library.ucsf.edu\/pdf\/brr13j10"},{"issue":"2","key":"10.1002\/14651858.CD010609-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/0333102412466968","article-title":"Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis","volume":"33","author":"Silberstein","year":"2013","journal-title":"Cephalagia"},{"key":"10.1002\/14651858.CD010609-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1046\/j.1526-4610.2001.01154-2.x","article-title":"Antiepileptic drugs: how they work in headache","volume":"41 Suppl 1","author":"Cutrer","year":"2001","journal-title":"Headache"},{"issue":"10","key":"10.1002\/14651858.CD010609-BIB0008|cit8","first-page":"478","article-title":"Gabapentine in the prophylaxis of migraine. A pilot study","volume":"14","author":"Jimenez","year":"1999","journal-title":"Neurologia"},{"issue":"2","key":"10.1002\/14651858.CD010609-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1526-4610.2001.111006119.x","article-title":"Efficacy of gabapentin in migraine prophylaxis","volume":"41","author":"Mathew","year":"2001","journal-title":"Headache"},{"issue":"8","key":"10.1002\/14651858.CD010609-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/00007611-199808000-00007","article-title":"Gabapentin for treatment of pain and tremor: a large case series","volume":"91","author":"Merren","year":"1998","journal-title":"Southern Medical Journal"},{"issue":"12","key":"10.1002\/14651858.CD010609-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1212\/01.WNL.0000100121.58594.11","article-title":"Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study","volume":"61","author":"Spira","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010609-BIB0012|cit12","first-page":"476","article-title":"Preliminary results of a double blind study with the new migraine prophylactic drug gabapentin","volume":"7 Suppl 6","author":"Wessely","year":"1987","journal-title":"Cephalalgia"},{"issue":"9","key":"10.1002\/14651858.CD010609-BIB0013|cit13","first-page":"717","article-title":"Classification of headache","volume":"179","author":"Ad Hoc Committee on the Classification of Headache of the National Institute of Neurological Diseases and Blindness","year":"1962","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD010609-BIB0014|cit14","unstructured":"Alderson P Green S Higgins JPT Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]; Appendix 5b In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd"},{"issue":"1","key":"10.1002\/14651858.CD010609-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/oxfordjournals.qjmed.a030141","article-title":"Economic and social impact of migraine","volume":"89","author":"Clarke","year":"1996","journal-title":"QJM"},{"issue":"9","key":"10.1002\/14651858.CD010609-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2174\/156802612800229215","article-title":"Recent progress in anticonvulsant drug research: strategies for anticonvulsant drug development and applications of antiepileptic drugs for non-epileptic central nervous system disorders","volume":"12","author":"Dalkara","year":"2012","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1002\/14651858.CD010609-BIB0017|cit17","unstructured":"Gabapentin User Reviews for Migraine at Drugs.com http:\/\/www.drugs.com\/comments\/gabapentin\/for-migraine.html"},{"issue":"2","key":"10.1002\/14651858.CD010609-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1017\/S0317167100047697","article-title":"Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey","volume":"20","author":"Edmeads","year":"1993","journal-title":"Canadian Journal of Neurological Sciences"},{"issue":"9","key":"10.1002\/14651858.CD010609-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","article-title":"EFNS guideline on the drug treatment of migraine\u2014revised report of an EFNS task force","volume":"16","author":"Evers","year":"2009","journal-title":"European Journal of Neurology"},{"issue":"9859","key":"10.1002\/14651858.CD010609-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2013","journal-title":"Lancet"},{"issue":"7211","key":"10.1002\/14651858.CD010609-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010609-BIB0022|cit22","first-page":"1","article-title":"The International Classification of Headache Disorders: 2nd edition","volume":"24 Suppl 1","author":"Headache Classification Subcommittee of the International Headache Society","year":"2004","journal-title":"Cephalalgia"},{"key":"10.1002\/14651858.CD010609-BIB0023|cit23","first-page":"1","article-title":"Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain","volume":"8 Suppl 7","author":"Headache Classification Committee of the International Headache Society","year":"1988","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1002\/14651858.CD010609-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD010609-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp0808659","article-title":"The Neurontin legacy \u2014marketing through misinformation and manipulation","volume":"360","author":"Landefeld","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010609-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","article-title":"The cost of headache disorders in Europe: the Eurolight project","volume":"19","author":"Linde","year":"2012","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD010609-BIB0027|cit27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010610","article-title":"Topiramate for the prophylaxis of episodic migraine in adults","author":"Linde","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD010609-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010611","article-title":"Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults","author":"Linde","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD010609-BIB0029|cit29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010609","article-title":"Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults","author":"Linde","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD010609-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010608","article-title":"Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults","author":"Linde","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010609-BIB0031|cit31","unstructured":"Mayo Clinic Staff Migraine: Treatments and drugs http:\/\/www.mayoclinic.com\/health\/migraine-headache\/DS00120\/DSECTION=treatments-and-drugs"},{"key":"10.1002\/14651858.CD010609-BIB0032|cit32","unstructured":"McCrory DC Report on gabapentin (Neurontin) for migraine prophylaxis: evaluation of efficacy, effectiveness and marketing. Expert consultant\u2019s report. August 11, 2008 Available at: http:\/\/dida.library.ucsf.edu\/pdf\/oxx18q10"},{"key":"10.1002\/14651858.CD010609-BIB0033|cit33","volume-title":"An Evidence-based Resource for Pain Relief","author":"McQuay","year":"1998"},{"issue":"8","key":"10.1002\/14651858.CD010609-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/j.1468-1331.2012.03681.x","article-title":"Self-medication of regular headache: a community pharmacy-based survey","volume":"19","author":"Mehuys","year":"2012","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD010609-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1468-2982.2006.01172.x","article-title":"New appendix criteria open for a broader concept of chronic migraine","volume":"26","author":"Olesen","year":"2006","journal-title":"Cephalalgia"},{"key":"10.1002\/14651858.CD010609-BIB0036|cit36","first-page":"331","article-title":"Antiepileptic drugs","volume-title":"Basic and Clinical Pharmacology","author":"Porter","year":"1992"},{"issue":"2 Suppl 2","key":"10.1002\/14651858.CD010609-BIB0037|cit37","first-page":"S1","article-title":"Canadian Headache Society guideline for migraine prophylaxis","volume":"39","author":"Pringsheim","year":"2012","journal-title":"Canadian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD010609-BIB0038|cit38","unstructured":"U.S.D.J Saris P Findings of fact and conclusions of law, In re Neurontin Marketing and Sales Practices Litigation. Civil Action No. 04-cv-10739-PBS, 2010 WL 4325225; 3 November 2010 Available at: http:\/\/pacer.mad.uscourts.gov\/dc\/cgi-bin\/recentops.pl?filename=saris\/pdf\/ucl%20opinion.pdf"},{"issue":"7","key":"10.1002\/14651858.CD010609-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/01.wnl.0000297551.27191.70","article-title":"Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study","volume":"70","author":"Silberstein","year":"2008","journal-title":"Neurology"},{"issue":"17","key":"10.1002\/14651858.CD010609-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD010609-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0333102411417901","article-title":"Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators","volume":"32","author":"Tfelt-Hansen","year":"2012","journal-title":"Cephalalgia"},{"issue":"20","key":"10.1002\/14651858.CD010609-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMsa0906126","article-title":"Outcome reporting in industry-sponsored trials of gabapentin for off-label use","volume":"361","author":"Vedula","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010609-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002761","article-title":"Drugs for preventing migraine headaches in children","author":"Victor","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010609-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001133.pub3","article-title":"Anticonvulsant drugs for acute and chronic pain","author":"Wiffen","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010609-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003226.pub2","article-title":"Anticonvulsant drugs for migraine prophylaxis","author":"Chronicle","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD010609-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1468-2982.2008.01571.x","article-title":"Anticonvulsants in migraine prophylaxis: a Cochrane review","volume":"28","author":"Mulleners","year":"2008","journal-title":"Cephalalgia"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD010609\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T02:17:07Z","timestamp":1714443427000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010609"}},"subtitle":[],"editor":[{"name":"Cochrane Pain, Palliative and Supportive Care Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,6,24]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010609","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,24]]}}}